Vitiligo after immune checkpoint inhibitor therapy in a woman with metastatic melanoma
| Autor: | Dwan-Ying Chang, Ming-Han Yang |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Cultural Studies
Oncology Linguistics and Language History medicine.medical_specialty Metastatic melanoma medicine.drug_class medicine.medical_treatment Immune checkpoint inhibitors Vitiligo Monoclonal antibody lcsh:RC254-282 Language and Linguistics 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Internal medicine Medicine Hypopigmentation business.industry Melanoma Immunotherapy lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease 030220 oncology & carcinogenesis Anthropology medicine.symptom Nivolumab business |
| Zdroj: | Journal of Cancer Research and Practice, Vol 5, Iss 4, Pp 161-164 (2018) |
| ISSN: | 2311-3006 |
| DOI: | 10.1016/j.jcrpr.2018.07.002 |
| Popis: | Historically, the median overall survival of patients with metastatic melanoma was less than one year. The recent advent of immunotherapy has changed the outlook dramatically and made long-term disease control achievable. Nivolumab, a monoclonal antibody to programmed cell death 1 (anti-PD1), has been proved to prolong survival in patients with metastatic melanoma. Vitiligo is a skin disorder characterized by the loss of color, and the postulated mechanism is immune-mediated destruction of melanocytes. Anti-PD1 treatment related to vitiligo has been reported to be associated with a favorable response in patients with melanoma. Here we present the case of a 61-year-old woman who received nivolumab for metastatic melanoma. After 6 months of nivolumab therapy, the patient experienced scattered hypopigmentation on her face, chest, and back. Durable response was noticed according to the follow-up images even after nivolumab was discontinued. Keywords: Immunotherapy, Melanoma, Vitiligo |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|